Pharmacological Approaches in the Treatment of COVID-19: Current Situation
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.25756/rpf.v12i1-2.238 |
Resumo: | The pandemic outbreak of COVID-19, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been creating unprecedent challenges to Public Health Systems. One of the most active areas in fighting this pandemic has been unmistakably the development of efficacious therapies for treatment of this disease. Taking into account that the “time-factor” is the limiting step of the, usually long, medicine development process, one of the most pursued approach has been the research of medicines already available in the market with approved indications for other diseases, the process known as “drug repurposing”, in an attempt to a faster pathway to a therapy with established efficacy and safety. There are also a few experimental medicinal substances that exhibited early indications of efficacy and are therefore also being evaluated for the treatment of COVID-19. In this context, two main pharmacological approaches have prevailed: antiviral therapies that intend to reduce the replicating and infectious ability of SARS--CoV-2; and immunomodulatory therapies with the aim of limiting the inflammatory response by the immune system towards the infection and the potential development of acute respiratory distress syndrome and even multiple organ dysfunction associated to septic shock. Simultaneously to the development of potential treatments for this infection, an unprecedent effort has been seen towards a development of an efficacious vaccine that allows to reduce the risk of disease development, especially in the higher-risk groups. This review aims to summarize, at this time, the major advancements in the treatment of COVID-19, including the successes, failures, lessons learned and the hopes for the future. |
id |
RCAP_7ea9d802bb04b6e3e65b0fef4909a7f4 |
---|---|
oai_identifier_str |
oai:ojs.farmacoterapia.pt:article/276 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Pharmacological Approaches in the Treatment of COVID-19: Current SituationAbordagens Farmacológicas na Terapêutica da COVID-19: Ponto de SituaçãoThe pandemic outbreak of COVID-19, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been creating unprecedent challenges to Public Health Systems. One of the most active areas in fighting this pandemic has been unmistakably the development of efficacious therapies for treatment of this disease. Taking into account that the “time-factor” is the limiting step of the, usually long, medicine development process, one of the most pursued approach has been the research of medicines already available in the market with approved indications for other diseases, the process known as “drug repurposing”, in an attempt to a faster pathway to a therapy with established efficacy and safety. There are also a few experimental medicinal substances that exhibited early indications of efficacy and are therefore also being evaluated for the treatment of COVID-19. In this context, two main pharmacological approaches have prevailed: antiviral therapies that intend to reduce the replicating and infectious ability of SARS--CoV-2; and immunomodulatory therapies with the aim of limiting the inflammatory response by the immune system towards the infection and the potential development of acute respiratory distress syndrome and even multiple organ dysfunction associated to septic shock. Simultaneously to the development of potential treatments for this infection, an unprecedent effort has been seen towards a development of an efficacious vaccine that allows to reduce the risk of disease development, especially in the higher-risk groups. This review aims to summarize, at this time, the major advancements in the treatment of COVID-19, including the successes, failures, lessons learned and the hopes for the future.A pandemia da doença COVID-19, causada pelo novo coronavírus associado à síndrome respiratória aguda (SARS-CoV-2) tem criado desafios à Saúde Pública nunca antes experienciados. Uma das áreas mais ativas no combate à pandemia tem sido inequivocamente o desenvolvimento de terapêuticas eficazes para o tratamento desta doença. Tendo em consideração que o fator tempo é nesta situação o fator limitante do processo, normalmente longo, do desenvolvimento de medicamentos, uma das abordagens mais utilizadas tem sido a investigação de medicamentos existentes no mercado com indicações aprovadas para outras doenças, o chamado “repurposing” de medicamentos, na tentativa de obter terapêuticas em que rapidamente se consiga caracterizar a sua eficácia e segurança. Existem também alguns fármacos, ainda experimentais, que demonstraram indícios precoces de eficácia e que se encontram também a ser avaliados para tratamento da COVID-19. Neste contexto, duas abordagens farmacológicas têm prevalecido: as terapêuticas antivirais que pretendem reduzir a capacidade replicadora e infeciosa do SARS-CoV-2; e as terapêuticas imunomoduladoras cujo objetivo será limitar a resposta inflamatória exacerbada do sistema imunitário à infeção, e o potencial desenvolvimento de síndrome de dificuldade respiratória aguda e até de disfunção múltipla de órgãos associada a choque séptico. Paralelamente ao desenvolvimento de potenciais tratamentos para a infeção, tem-se verificado um esforço incomparável no desenvolvimento de uma vacina eficaz que permita reduzir o risco de desenvolver a doença, principalmente nos grupos de maior risco. Esta revisão tem como objetivo resumir, até à data da sua escrita, os maiores avanços na terapêutica da COVID-19, incluindo sucessos e insucessos, as aprendizagens ao longo do processo, lançando as esperanças para o futuro.Formifarma2020-07-21info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.25756/rpf.v12i1-2.238https://doi.org/10.25756/rpf.v12i1-2.238Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 12 No 1-2 (2020): Janeiro/Fevereiro/Março e Abril/Maio/Junho; 27-38Revista Portuguesa de Farmacoterapia; v. 12 n. 1-2 (2020): Janeiro/Fevereiro/Março e Abril/Maio/Junho; 27-382183-73411647-354Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://revista.farmacoterapia.pt/index.php/rpf/article/view/276http://revista.farmacoterapia.pt/index.php/rpf/article/view/276/252Direitos de Autor (c) 2020 Revista Portuguesa de Farmacoterapiahttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessRocha, João2023-09-01T04:34:42Zoai:ojs.farmacoterapia.pt:article/276Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:11:41.185459Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation Abordagens Farmacológicas na Terapêutica da COVID-19: Ponto de Situação |
title |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation |
spellingShingle |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation Rocha, João |
title_short |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation |
title_full |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation |
title_fullStr |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation |
title_full_unstemmed |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation |
title_sort |
Pharmacological Approaches in the Treatment of COVID-19: Current Situation |
author |
Rocha, João |
author_facet |
Rocha, João |
author_role |
author |
dc.contributor.author.fl_str_mv |
Rocha, João |
description |
The pandemic outbreak of COVID-19, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been creating unprecedent challenges to Public Health Systems. One of the most active areas in fighting this pandemic has been unmistakably the development of efficacious therapies for treatment of this disease. Taking into account that the “time-factor” is the limiting step of the, usually long, medicine development process, one of the most pursued approach has been the research of medicines already available in the market with approved indications for other diseases, the process known as “drug repurposing”, in an attempt to a faster pathway to a therapy with established efficacy and safety. There are also a few experimental medicinal substances that exhibited early indications of efficacy and are therefore also being evaluated for the treatment of COVID-19. In this context, two main pharmacological approaches have prevailed: antiviral therapies that intend to reduce the replicating and infectious ability of SARS--CoV-2; and immunomodulatory therapies with the aim of limiting the inflammatory response by the immune system towards the infection and the potential development of acute respiratory distress syndrome and even multiple organ dysfunction associated to septic shock. Simultaneously to the development of potential treatments for this infection, an unprecedent effort has been seen towards a development of an efficacious vaccine that allows to reduce the risk of disease development, especially in the higher-risk groups. This review aims to summarize, at this time, the major advancements in the treatment of COVID-19, including the successes, failures, lessons learned and the hopes for the future. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-07-21 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.25756/rpf.v12i1-2.238 https://doi.org/10.25756/rpf.v12i1-2.238 |
url |
https://doi.org/10.25756/rpf.v12i1-2.238 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revista.farmacoterapia.pt/index.php/rpf/article/view/276 http://revista.farmacoterapia.pt/index.php/rpf/article/view/276/252 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2020 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2020 Revista Portuguesa de Farmacoterapia http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Formifarma |
publisher.none.fl_str_mv |
Formifarma |
dc.source.none.fl_str_mv |
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 12 No 1-2 (2020): Janeiro/Fevereiro/Março e Abril/Maio/Junho; 27-38 Revista Portuguesa de Farmacoterapia; v. 12 n. 1-2 (2020): Janeiro/Fevereiro/Março e Abril/Maio/Junho; 27-38 2183-7341 1647-354X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799129986998730752 |